Author

Peng-Peng Lu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Targeting the Metabolic-Immune Regulator SLC35F6 Enhances Temozolomide and Anti-PD-L1 Therapy in Glioma.

A dual-ligand nanoplatform designed to facilitate trans-BBB delivery of siSLC35F6, TMZ, and an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody (α-PD-L1) monoclonal antibody is developed.

Peng-Peng Lu, Wei Wang, Bing Lu et al. · Cancer Letters · 0 citations